Cardiogenic Shock

Categories: Blood diseases, Cardiovascular diseases, Rare diseases

Aliases & Classifications for Cardiogenic Shock

MalaCards integrated aliases for Cardiogenic Shock:

Name: Cardiogenic Shock 59 63 33
Shock, Cardiogenic 72
Shock Cardiogenic 55


Orphanet epidemiological data:

cardiogenic shock
Prevalence: 1-5/10000 (Europe);


External Ids:

ICD10 33 R57.0
ICD10 via Orphanet 34 R57.0
UMLS via Orphanet 73 C0036980
Orphanet 59 ORPHA97292
UMLS 72 C0036980

Summaries for Cardiogenic Shock

PubMed Health : 63 About cardiogenic shock: Cardiogenic (kar-dee-oh-JE-nik) shock is a condition in which a suddenly weakened heart isn't able to pump enough blood to meet the body's needs. The condition is a medical emergency and is fatal if not treated right away. The most common cause of cardiogenic shock is damage to the heart muscle from a severe heart attack. However, not everyone who has a heart attack has cardiogenic shock. In fact, on average, only about 7 percent of people who have heart attacks develop the condition. If cardiogenic shock does occur, it's very dangerous. When people die from heart attacks in hospitals, cardiogenic shock is the most common cause of death.

MalaCards based summary : Cardiogenic Shock, also known as shock, cardiogenic, is related to acute myocardial infarction and pulmonary edema, and has symptoms including syncope and shock without mention of trauma. An important gene associated with Cardiogenic Shock is NPPB (Natriuretic Peptide B), and among its related pathways/superpathways are Selenium Micronutrient Network and IL-6 signaling pathway. The drugs Dalteparin and Enoxaparin have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and liver.

Wikipedia : 75 Cardiogenic shock (CS) is a medical emergency resulting from inadequate blood flow due to the... more...

Related Diseases for Cardiogenic Shock

Diseases related to Cardiogenic Shock via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 434)
# Related Disease Score Top Affiliating Genes
1 acute myocardial infarction 31.4 PLAT NPPB CRP
2 pulmonary edema 31.3 NPPB CRP
3 inferior myocardial infarction 31.3 PLAT NPPB
4 anterolateral myocardial infarction 31.0 PLAT NPPB
5 myocarditis 31.0 NPPB IL6
6 heart valve disease 30.6 NPPB CRP
7 cardiac rupture 30.6 PLAT CRP
8 myocardial infarction 30.5 PLAT NPPB IL6 CRP ADM
9 aortic valve disease 2 30.4 NPPB CRP
10 pulmonary embolism 30.4 PLAT NPPB CRP
11 pulmonary hypertension 30.3 PLAT NPPB ADM
12 coronary artery anomaly 30.3 PLAT NPPB CRP
13 renal hypertension 30.2 NPPB ADM
14 pulmonary hypertension, primary, 1 30.1 NPPB ADM
15 infective endocarditis 30.1 IL6 CRP
16 chronic thromboembolic pulmonary hypertension 30.1 NPPB CRP
17 peripheral artery disease 29.9 IL6 CRP
18 exanthem 29.8 IL6 CRP
19 coronary stenosis 29.8 NPPB IL6 CRP
20 intermediate coronary syndrome 29.8 PLAT IL6 CRP
21 hand, foot and mouth disease 29.8 NPPB IL6
22 endocarditis 29.7 PLAT IL6 CRP
23 atrial fibrillation 29.7 PLAT NPPB CRP
24 leptospirosis 29.7 IL6 CRP
25 bacterial pneumonia 29.7 IL6 CRP
26 systolic heart failure 29.7 NPPB IL6 CRP
27 peripheral vascular disease 29.7 PLAT IL6 CRP
28 purpura 29.6 IL6 CRP
29 vascular disease 29.6 PLAT IL6 CRP
30 pericardial effusion 29.6 NPPB IL6 CRP
31 aortic valve disease 1 29.6 NPPB CRP
32 end stage renal failure 29.5 IL6 CRP
33 mouth disease 29.5 IL6 CRP
34 acute cystitis 29.5 IL6 CRP
35 kawasaki disease 29.5 NPPB IL6 CRP
36 brucellosis 29.4 IL6 CRP
37 temporal arteritis 29.4 IL6 CRP
38 lyme disease 29.4 IL6 CRP
39 bacterial infectious disease 29.4 IL6 CRP
40 aortic disease 29.4 IL6 CRP
41 takayasu arteritis 29.3 IL6 CRP
42 pericarditis 29.3 NPPB IL6 CRP
43 peritonitis 29.3 IL6 CRP
44 acute pancreatitis 29.2 IL6 CRP
45 kidney disease 29.1 NPPB IL6 CRP ADM
46 arteries, anomalies of 29.1 PLAT NPPB IL6 CRP
47 angina pectoris 29.0 PLAT NPPB IL6 CRP
48 atherosclerosis susceptibility 28.7 IL6 CRP
49 coronary heart disease 1 28.7 PLAT NPPB IL6 CRP
50 heart disease 28.6 PLAT NPPB IL6 CRP ADM

Comorbidity relations with Cardiogenic Shock via Phenotypic Disease Network (PDN): (show all 16)

Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Aortic Valve Disease 1
Cardiac Arrest Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Intermediate Coronary Syndrome Kidney Disease
Mitral Valve Disease Peripheral Vascular Disease
Respiratory Failure Third-Degree Atrioventricular Block
Tricuspid Valve Disease Ventricular Fibrillation, Paroxysmal Familial, 1

Graphical network of the top 20 diseases related to Cardiogenic Shock:

Diseases related to Cardiogenic Shock

Symptoms & Phenotypes for Cardiogenic Shock

UMLS symptoms related to Cardiogenic Shock:

syncope, shock without mention of trauma

Drugs & Therapeutics for Cardiogenic Shock

PubMed Health treatment related to Cardiogenic Shock: 63

Cardiogenic shock is life threatening and requires emergency medical treatment. The condition usually is diagnosed after a person has been admitted to a hospital for a heart attack. If the person isn't already in a hospital, emergency treatment can start as soon as medical personnel arrive. The first goal of emergency treatment for cardiogenic shock is to improve the flow of blood and oxygen to the body’s organs. Sometimes both the shock and its cause are treated at the same time. For example, doctors may quickly open a blocked blood vessel that's damaging the heart. Often, this can get the patient out of shock with little or no additional treatment.

Drugs for Cardiogenic Shock (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 220)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Dalteparin Approved Phase 4 9005-49-6
Enoxaparin Approved Phase 4 9005-49-6 772
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
Racepinephrine Approved Phase 4 329-65-7 838
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
Abciximab Approved Phase 4 143653-53-6
Probucol Approved, Investigational Phase 4 23288-49-5 4912
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
Streptokinase Approved, Investigational Phase 4 9002-01-1
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
Atorvastatin Approved Phase 4 134523-00-5 60823
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
Dobutamine Approved Phase 4 34368-04-2 36811
Norepinephrine Approved Phase 4 51-41-2 439260
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
tannic acid Approved Phase 4 1401-55-4
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
Ticagrelor Approved Phase 4 274693-27-5 9871419
Cangrelor Approved Phase 4 163706-06-7 9854012
carbamide peroxide Approved Phase 4 124-43-6
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616 46835353
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
Mycophenolic acid Approved Phase 4 24280-93-1 446541
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
Tenecteplase Approved Phase 4 191588-94-0
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
36 Protective Agents Phase 4
37 Autonomic Agents Phase 4
38 Anticoagulants Phase 4
39 Heparin, Low-Molecular-Weight Phase 4
40 Neuroprotective Agents Phase 4
41 Gastrointestinal Agents Phase 4
42 Methylprednisolone Acetate Phase 4
43 Antiemetics Phase 4
44 Antineoplastic Agents, Hormonal Phase 4
45 Prednisolone acetate Phase 4
46 Thromboplastin Phase 4
47 Tissue Plasminogen Activator Phase 4
48 Plasminogen Phase 4
49 Adrenergic Agonists Phase 4
50 Epinephryl borate Phase 4

Interventional clinical trials:

(show top 50) (show all 242)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Thrombus Aspiration in Patients With ST-segment Elevation Myocardial Infarction (STEMI) Unknown status NCT02606435 Phase 4
2 The Effect of 6-Methyl-Prednisolone on Organ Dysfunction and Mortality of Patients With Unresolving Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
3 Comparison of Low-Molecular-Weight Heparin (LMWH) and Unfractionated Heparin (UFH) in Combination With Thrombolytic Treatment of Acute Massive Pulmonary Thromboembolism Unknown status NCT01956955 Phase 4 enoxaparin ,alteplase, unfractionated heparin
4 Prospective Randomized Multicenter Study Comparing Immediate Multivessel Revascularization by PCI Versus Culprit Lesion PCI With Staged Non-culprit Lesion Revascularization in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock Completed NCT01927549 Phase 4
5 Optimizing the Use of Vasopressor After Coronary Reperfusion in Cardiogenic Shock Secondary to Myocardial Infarction. Pathophysiological Study Comparing the Efficacy and Cardio-circulatory Tolerability of Epinephrine and Norepinephrine Completed NCT01367743 Phase 4 epinephrine perfusion;norepinephrine perfusion
6 Randomized Clinical Study of Intraaortic Balloon Pump Use in Cardiogenic Shock Complicating Acute Myocardial Infarction Completed NCT00491036 Phase 4
7 Left Ventricular Assist Device (Impella LP 2.5) vs. Intraaortic Balloon Counterpulsation (IABP) in Patients With Cardiogenic Shock and Acute Coronary Syndromes Completed NCT00417378 Phase 4
8 Routine Upfront Abciximab Versus Standard Peri-Procedural Therapy in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock PRAGUE-7 Trial. Completed NCT00420030 Phase 4 Abciximab
9 Safety and Efficacy of Levosimendan in Patients With Acute Myocardial Infarction Complicated by Symptomatic Left Ventricular Failure. Completed NCT00324766 Phase 4 levosimendan;placebo,
10 Thrombus Aspiration Before Standard Primary Angioplasty Improves Myocardial Reperfusion in Acute Myocardial Infarction. Completed NCT00257153 Phase 4
11 Prospective, Randomized Trial of Rapamycin- and Zotarolimus-eluting Stents for the Reduction of Coronary Restenosis Completed NCT00598533 Phase 4
12 Intracoronary Stenting and Angiographic Results: ORSIRO Stents Versus Xience PRIME Stents Assessed by Optical Coherence Tomography Completed NCT01594736 Phase 4 ORSIRO
13 Addition of Dexmedetomidine to Ropivacaine-induced Supraclavicular Plexus Block, a Randomized Controlled Study Completed NCT02630290 Phase 4 Ropivacaine;Ropivacaine + Dexmedetomidine
14 Pilot Randomized Clinical Trial Comparing the Efficacy of Two Different Hypothermia Temperatures for Treatment of Comatose Patients Recovered From an Out-of-hospital Cardiac Arrest Completed NCT01155622 Phase 4
15 ON Pump vs OFF Pump Myocardial Revascularization in High Risk Patients: a Randomized Study Completed NCT01290952 Phase 4
16 Clopidogrel Or Metoprolol in Myocardial Infarction Trial Completed NCT00222573 Phase 4 clopidogrel and metoprolol
17 Pain, Agitation and Delirium Protocol in Ventilated Patients in the Duke CICU Completed NCT02903407 Phase 4 Midazolam;Propofol;Dexmedetomidine
18 Efficacy and Safety Evaluation of Recombinant Streptokinase and Urokinase in the Treatment of Pulmonary Embolism: A Multi-Center, Randomized Controlled Trial in China Completed NCT00968929 Phase 4 Recombinant Streptokinase;Urokinase
19 A Randomised Trial on Early Stress Nuclear Scan for Patients Presented to the Emergency Department (ED) With Chest Pain But Non-diagnostic Electrocardiography-Acute Chest Pain Treatment and Evaluation (ACTION) Study Completed NCT00434564 Phase 4
20 CompariSon of Manual Aspiration With Rheolytic Thrombectomy in Patients Undergoing Primary PCI. The SMART-PCI Trial Completed NCT01281033 Phase 4
21 Comparison of Efficiency of High Dose Atorvastatin and Endothelial Progenitor-Capture Stents and Bare Metal Stents in Reduction of Neointimal Formation in Patients With Non ST-Segment Elevation Acute Coronary Syndromes Completed NCT00494247 Phase 4
22 Early Effect Of Bezafibrate On Fibrinogen Levels, Inflammatory Response And Clinical Impact, In Patients With ST Elevation Acute Myocardial Infarction Completed NCT02291796 Phase 4 Bezafibrate
23 Optical Coherence Tomography Assessment of Gender diVersity In Primary Angioplasty: The OCTAVIA Trial Completed NCT02577965 Phase 4
24 Evaluation of Late Clinical Events After Drug-eluting Versus Bare-metal Stents in Patients at Risk: BAsel Stent Kosten Effektivitäts Trial - PROspective Validation Examination Part II (BASKET-PROVE II) Completed NCT01166685 Phase 4
25 Effect of Ivabradine on Heart Rate and Hemodynamics in Patients With Stage D Heart Failure (HF)/Cardiogenic Shock on Dobutamine Treatment Recruiting NCT03387605 Phase 4 Ivabradine;Placebo
26 Comparison of Milrinone Versus Dobutamine in a Heterogeneous Population of Critically Ill Patients Recruiting NCT03207165 Phase 4 Milrinone;Dobutamine
27 Cangrelor Versus Ticagrelor In Patients With Acute Myocardial Infarction Complicated With Initial Cardiogenic Shock Recruiting NCT03551964 Phase 4 Cangrelor;Ticagrelor
28 Impact of Early CRRT or Beta-blocker Intervention in Patients Receiving VA-ECMO Support on 30-day Mortality: A 2 × 2 Partial Factorial Randomized Controlled Trial Recruiting NCT03549923 Phase 4 Esmolol;Standard care
29 China Tongxinluo Study for Myocardial Protection in Patients With Acute Myocardial Infarction Recruiting NCT03792035 Phase 4 Tongxinluo;Placebos
30 Comparing a Diuretic Vascular Filling in the Initial Management of Acute Pulmonary Embolism With Right Ventricular Dysfunction Normotensive Recruiting NCT02531581 Phase 4 Furosemide;NaCl 9% isotonic
31 Intracoronary Analysis of Cardiac Allograft Vasculopathy in Comparison to Coronary Artery Disease by Means of Optical Coherence Tomography Recruiting NCT02254668 Phase 4
32 Pharmacokinetic/Pharmacodynamic Effects of add-on Antiplatelet Therapy With Parenteral Cangrelor as Compared to Standard Dual Antiplatelet Treatment in Patients With ST-elevation Myocardial Infarction Complicated by Out-of-hospital Cardiac Arrest and Treated With Targeted Temperature Management Recruiting NCT03273075 Phase 4 Cangrelor;Placebo;Prasugrel;Ticagrelor
33 Randomized Clinical Study of Extra-Corporal Life Support in Cardiogenic Shock Complicating Acute Myocardial Infarction Active, not recruiting NCT02544594 Phase 4
34 Efficacy and Safety on Heart Rate Control With Ivabradine on Cardiogenic Shock (ES-FISH) Not yet recruiting NCT03437369 Phase 4 Ivabradine Oral Tablet
35 Ivabradine in Stage D Heart Failure Patients on Chronic Inotropes: A Pilot Study Not yet recruiting NCT03631654 Phase 4 Ivabradine;Placebos
36 National Multicenter Randomized Trial, Comparing Two Treatments of Myocardial Infarction Complicated With Cardiogenic Shock: Standard Treatment vs Standard Treatment Plus ECLS (Extracorporeal Life Support) Terminated NCT00314847 Phase 4
37 A Randomized Comparative Effectiveness Study of Routine Versus Selective Use of Fractional Flow Reserve (FFR) to Guide Non-Emergent Percutaneous Coronary Intervention (PCI) Terminated NCT02000661 Phase 4
38 TRIANA: A Randomized Trial to Compare the Efficay and Safety of Thrombolysis With Primary Angioplasty as Initial Reperfusion Therapy in Older Patients (>= 75 Years Old) With Acute Myocardial Infarction Terminated NCT00257309 Phase 4 Tenecteplase + UFH (+ clopidogrel, since 01/97)
39 Efficacy of Levosimendan in the Critically Ill Patients With Unstable Hemodynamics (the LICI Study) - A Double Blind Randomized Pilot Study Unknown status NCT00093301 Phase 2, Phase 3 Levosimendan;Dobutamine
40 Adjunctive Mild Hypothermia Therapy to Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction Complicated With Shock: A Feasibility Study Unknown status NCT00846222 Phase 3
41 Impact of One Stage Compared With Multistaged PCI Complete Revascularization on Clinical Outcome in Multivessel NSTEMI Patients. Smile Trial Unknown status NCT01478984 Phase 3
42 Efficacy of Furosemide Versus Vascular Filling in Patients With Acute Myocardial Infarction With Right Ventricular Extension: A Multicentric Randomized Controlled Trial Unknown status NCT02905760 Phase 3 Furosemide;Placebo filling;Placebo furosemide;Vascular filling
43 Evaluation of N-acetylcystein on Biomarkers of Platelet Activation , Cardiac Necrosis and Coronary Reperfusion in Patients Undergoing Percutaneous Coronary Intervention Unknown status NCT01741207 Phase 3 N-acetylcystein
44 Impact of Intravenous Exenatide Versus Insulin on Quality of Life in Cardiac Surgery Patients: an Ancillary Study of the ExSTRESS Phase II/III Clinical Trial Unknown status NCT02432976 Phase 2, Phase 3 Exenatide;Insulin
45 Effect of Remote Ischemic Preconditioning on Incidence of Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Graft Surgery A Randomized Controlled Trial Unknown status NCT01500369 Phase 3
46 Multicenter Open Lable Randomized Comparative Study of Efficacy and Safety of Single Bolus Injection of Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Tenecteplase (Metalyse) in STEMI Patients Unknown status NCT02301910 Phase 3 Recombinant staphylokinase;Tenecteplase
47 Shock Trial: Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. Completed NCT00000552 Phase 3 thrombolytic therapy
48 Comparison of Dopamine and Norepinephrine as the First Vasopressor Agent in the Management of Shock Completed NCT00314704 Phase 3 dopamine versus norepinephrine
49 The Safety and Efficacy of Eptifibatide-Facilitated Percutaneous Coronary Angioplasty Versus Primary Percutaneous Coronary Angioplasty Alone Completed NCT00251823 Phase 3 Eptifibatide facilitated PCI
50 N-Acetylcysteine in Critically Ill Patients Undergoing Contrast Enhanced Computed Tomography: A Randomized Trial Completed NCT00830193 Phase 2, Phase 3 N-acetylcysteine;D5W Placebo

Search NIH Clinical Center for Cardiogenic Shock

Inferred drug relations via UMLS 72 / NDF-RT 51 :

Digitalis preparation
inamrinone lactate

Genetic Tests for Cardiogenic Shock

Anatomical Context for Cardiogenic Shock

MalaCards organs/tissues related to Cardiogenic Shock:

Heart, Kidney, Liver, Lung, Testes, Brain, Endothelial

Publications for Cardiogenic Shock

Articles related to Cardiogenic Shock:

(show top 50) (show all 10400)
# Title Authors PMID Year
Cardiac troponin I levels in acute pulmonary embolism. 9 38
20222345 2009
Impaired plasma B-type natriuretic peptide clearance in human septic shock. 9 38
18679125 2008
Excimer laser in myocardial infarction: a comparison between STEMI patients with established Q-wave versus patients with non-STEMI (non-Q). 9 38
17426922 2008
B-type natriuretic peptide and its molecular precursor in myocardial infarction complicated by cardiogenic shock. 9 38
17448415 2007
Time-to-reperfusion therapy influences outcome of patients with myocardial infarction subjected to facilitated PCI. 9 38
19758922 2005
Natriuretic peptides and E-selectin as predictors of acute deterioration in patients with inotrope-dependent heart failure. 9 38
15848333 2005
Plasma brain natriuretic peptide reflects left ventricular function during percutaneous cardiopulmonary support. 9 38
14726055 2004
Quantitative measurement of the novel human plasma protein, IHRP, by sandwich ELISA. 9 38
11256472 2001
Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries. 9 38
10099909 1999
Impact of time to treatment with tissue plasminogen activator on morbidity and mortality following acute myocardial infarction (The second National Registry of Myocardial Infarction). 9 38
9708650 1998
[Factors predictive of early mortality after acute myocardial infarction]. 9 38
8953932 1996
Editorial commentary: The Checklist Manifesto: Cardiogenic Shock Edition. 38
30553705 2019
Mechanical circulatory support for patients with cardiogenic shock. 38
30573276 2019
Discriminatory power of scoring systems for outcome prediction in patients with extracorporeal membrane oxygenation following cardiovascular surgery†. 38
30789227 2019
Management of Peripheral Venoarterial Extracorporeal Membrane Oxygenation in Cardiogenic Shock. 38
31219839 2019
Revascularisation and mechanical circulatory support in patients with ischaemic cardiogenic shock. 38
31129613 2019
Comparison of Clinical Outcomes: Bivalirudin With Transfemoral Access Versus Heparin With Transradial Access in Patients With ST segment Elevation Myocardial Infarction. 38
31348072 2019
Clinical scenarios for use of transvalvular microaxial pumps in acute heart failure and cardiogenic shock - A European experienced users working group opinion. 38
31155332 2019
Treatment of acute limb ischemia in an Impella CP patient. 38
31104536 2019
Endovascular Extra-Anatomic Femoro-Popliteal Bypass for Limb Salvage in Chronic Critical Limb Ischemia. 38
31214761 2019
The Role of Venoarterial Extracorporeal Membrane Oxygenation in Postcardiotomy Cardiogenic Shock. 38
31351559 2019
Safety of direct true lumen cannulation after venous exsanguination: a study in a surviving porcine model†. 38
30809679 2019
A case of cardiogenic shock due to acute coronary syndrome successfully recovered by percutaneous and paracorporeal left ventricular assist device. 38
30937678 2019
Invasive Hemodynamic Predictors of Renal Outcomes after Percutaneous Coronary Interventions. 38
31394545 2019
Major publications in critical care pharmacotherapy literature in 2018. 38
31100708 2019
[Assessment and Acute Management of Decompensated Heart Valves in the Intensive Care Unit - a Current Review]. 38
31416106 2019
ECMO During Combined Heart-Kidney Transplantation: A Case Report. 38
31385822 2019
Incidence, Predictors, and Outcomes of Acute Ischemic Stroke Following Percutaneous Coronary Intervention. 38
31395220 2019
Preoperative intra-aortic balloon pump inserted in acute myocardial infarction patients without cardiogenic shock undergoing surgical coronary revascularization. 38
31387455 2019
Frequency of 30-day readmission and its causes after percutaneous coronary intervention in acute myocardial infarction complicated by cardiogenic shock. 38
30811833 2019
Utilization of Percutaneous Mechanical Circulatory Support Devices in Cardiogenic Shock Complicating Acute Myocardial Infarction and High-Risk Percutaneous Coronary Interventions. 38
31412669 2019
Percutaneous coronary intervention strategies in patients with acute myocardial infarction and multivessel disease: Completeness, timing, lesion assessment, and patient status. 38
31053505 2019
Lactate and other biomarkers as treatment target in cardiogenic shock. 38
31116111 2019
Advancements in the diagnostic workup, prognostic evaluation, and treatment of takotsubo syndrome. 38
31372789 2019
Nonischemic Causes of Cardiogenic Shock. 38
31262417 2019
Clinical characteristics and prognostic factors in acute coronary syndrome patients complicated with cardiogenic shock in Japan: analysis from the Japanese Circulation Society Cardiovascular Shock Registry. 38
30715570 2019
Ivosidenib induction therapy complicated by myopericarditis and cardiogenic shock: A case report and literature review. 38
31382862 2019
Impella CP use in patients with non-ischaemic cardiogenic shock. 38
31095902 2019
Assessment of microcirculation in cardiogenic shock. 38
31135392 2019
Protein-based cardiogenic shock patient classifier. 38
31204432 2019
Utilization of Palliative Care for Cardiogenic Shock Complicating Acute Myocardial Infarction: A 15-Year National Perspective on Trends, Disparities, Predictors, and Outcomes. 38
31315497 2019
Benefit of Primary Percutaneous Coronary Intervention in Elderly Patients With Cardiogenic Shock. 38
31395137 2019
Reply: Benefit of Primary Percutaneous Coronary Intervention in Elderly Patients With Cardiogenic Shock. 38
31395138 2019
Utilization and Outcomes of Temporary Mechanical Circulatory Support Devices in Cardiogenic Shock. 38
31204034 2019
Predictors of Mortality and Outcomes of Acute Severe Cardiogenic Shock Treated with the Impella Device. 38
31262498 2019
An overview of international cardiogenic shock guidelines and application in clinical practice. 38
31107307 2019
Inotropes and vasopressors use in cardiogenic shock: when, which and how much? 38
31166204 2019
Editorial: Cardiogenic shock: on the search for a breakthrough in outcome? 38
31246638 2019
Long-Term Outcomes of Left Main Bifurcation Double Stenting in Patients with STEMI and Cardiogenic Shock. 38
30385117 2019
Left Main Double Stenting for Patients with Cardiogenic Shock: The Faster the Better. 38
31248797 2019

Variations for Cardiogenic Shock

Expression for Cardiogenic Shock

Search GEO for disease gene expression data for Cardiogenic Shock.

Pathways for Cardiogenic Shock

Pathways related to Cardiogenic Shock according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways
11.47 PLAT IL6 CRP
Show member pathways
11.19 IL6 CRP
3 10.84 PLAT IL6
4 9.9 IL6 CRP

GO Terms for Cardiogenic Shock

Cellular components related to Cardiogenic Shock according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.35 PLAT NPPB IL6 CRP ADM
2 extracellular space GO:0005615 9.02 PLAT NPPB IL6 CRP ADM

Biological processes related to Cardiogenic Shock according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 defense response to Gram-positive bacterium GO:0050830 9.26 IL6 CRP
2 response to glucocorticoid GO:0051384 9.16 IL6 ADM
3 acute-phase response GO:0006953 8.96 IL6 CRP
4 negative regulation of lipid storage GO:0010888 8.62 IL6 CRP

Molecular functions related to Cardiogenic Shock according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 8.8 PLAT NPPB ADM

Sources for Cardiogenic Shock

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....